For most of human history, a diagnosis of a genetic disease was a life sentence. If your DNA carried a harmful mutation, there was nothing medicine could do about the root cause. Doctors could manage symptoms — transfuse blood, replace enzymes, prescribe painkillers — but the broken instruction in your genetic code remained, silently driving the disease forward.
That era is ending.
In December 2023, the FDA approved Casgevy, the first therapy built on CRISPR gene editing, for sickle cell disease. It was a proof of concept that reverberated across the entire field of medicine: we can now go into a patient's cells, find the genetic error, and fix it. Since then, the pipeline of gene editing and gene therapy candidates has exploded. Dozens of clinical trials are underway, targeting diseases that range from rare blood disorders to common killers like high cholesterol and heart disease.
Not every genetic disease will be cured by 2030. But a remarkable number are closer to a permanent fix than most people realize. Here are 10 genetic diseases where gene editing or gene therapy is most likely to deliver a functional cure within the next five years — ranked from the most advanced (already approved) to the most ambitious (still in clinical trials but showing extraordinary promise).
1. Sickle Cell Disease — Already Cured
What it is: Sickle cell disease (SCD) is caused by a single mutation in the HBB gene, which encodes the beta-globin protein in hemoglobin. This mutation causes red blood cells to deform into rigid, sickle-shaped cells that block blood vessels, triggering episodes of agonizing pain called vaso-occlusive crises (VOCs). SCD affects approximately 100,000 Americans and millions worldwide, disproportionately impacting people of African descent. Before gene therapy, the only curative option was a bone marrow transplant from a matched sibling donor — available to fewer than 20% of patients.
The gene editing approach: Casgevy (exagamglogene autotemcel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, uses CRISPR-Cas9 to disrupt the BCL11A gene in a patient's own blood stem cells ex vivo. Rather than correcting the sickle mutation directly, this elegant strategy reactivates fetal hemoglobin (HbF) — a form of hemoglobin that humans naturally produce before birth. Fetal hemoglobin carries oxygen just as effectively as normal adult hemoglobin and prevents the sickling process entirely.
Key data: In the pivotal CLIMB SCD-121 trial, 29 of 31 evaluable patients (93.5%) were completely free from vaso-occlusive crises for at least 12 consecutive months after treatment. Patients maintained fetal hemoglobin levels above 40% of total hemoglobin, compared to the less than 1% typical in untreated adults. Victoria Gray, the first American to receive the treatment in 2019, has remained essentially symptom-free for over six years.
Lead company: Vertex Pharmaceuticals / CRISPR Therapeutics
Status: FDA-approved (December 8, 2023). Also approved by the European Medicines Agency (EMA). A second gene therapy for SCD, Lyfgenia (bluebird bio), using a lentiviral vector rather than CRISPR, was approved on the same day.
Timeline: Already here. The challenge now is access — at a list price of approximately $2.2 million, and with a treatment process requiring months of hospitalization, scaling Casgevy to the hundreds of thousands of patients who need it remains the critical frontier.
"This is a victory for all those who have endured the suffering of sickle cell disease. To go from science fiction to science fact in my lifetime is something I never thought I would see." — Victoria Gray, first U.S. patient treated with CRISPR for sickle cell disease (NPR, December 2023) [1]
2. Beta-Thalassemia — Already Cured
What it is: Beta-thalassemia is a group of inherited blood disorders caused by mutations in the HBB gene that reduce or eliminate production of beta-globin, a key component of hemoglobin. In its most severe form — transfusion-dependent beta-thalassemia (TDT) — patients require blood transfusions every two to four weeks from early childhood to survive. Without transfusions, severe anemia leads to organ damage and death. Chronic transfusions cause iron overload, which itself damages the heart, liver, and endocrine organs.
The gene editing approach: The same Casgevy therapy approved for sickle cell disease also works for beta-thalassemia, because the underlying strategy — disrupting BCL11A to reactivate fetal hemoglobin — addresses the hemoglobin deficiency in both diseases. When fetal hemoglobin production ramps up, it compensates for the missing or defective adult beta-globin.
Key data: In clinical trials, 28 of 32 evaluable TDT patients (87.5%) achieved transfusion independence for at least 12 consecutive months. For patients who had received transfusions every few weeks since childhood, this outcome was life-changing. Additionally, Zynteglo (bluebird bio), a lentiviral gene therapy that inserts a functional copy of the beta-globin gene, showed that 89% of treated patients achieved transfusion independence in its pivotal trial.
Lead companies: Vertex/CRISPR Therapeutics (Casgevy); bluebird bio (Zynteglo)
Status: Casgevy received FDA approval for TDT in January 2024. Zynteglo was approved in August 2022.
Timeline: Already here. Two approved gene therapies — one using CRISPR editing, one using gene addition — offer curative options for TDT patients. Like sickle cell disease, the remaining barriers are cost, manufacturing capacity, and global access.
3. Hereditary Angioedema — Cure Expected by 2026
What it is: Hereditary angioedema (HAE) is a rare genetic disorder caused by mutations in the SERPING1 gene, which encodes C1-inhibitor, a protein that regulates the complement and contact activation systems. When C1-inhibitor is deficient or dysfunctional, patients experience sudden, unpredictable episodes of severe swelling (edema) in the face, throat, abdomen, and extremities. Throat swelling can be fatal if untreated. Approximately 1 in 50,000 people worldwide are affected. Current treatments require regular injections or infusions to prevent attacks — often every one to two weeks, indefinitely.
The gene editing approach: Intellia Therapeutics has developed NTLA-2002 (lonvuterkagene maspadenorepvovec, or "lonvo-z"), the first in vivo CRISPR-based gene editing therapy to reach Phase 3 trials. Delivered as a single intravenous infusion, lonvo-z uses lipid nanoparticles to carry CRISPR-Cas9 components directly to the liver, where they knock out the KLKB1 gene encoding prekallikrein. By eliminating prekallikrein, the therapy blocks production of bradykinin — the molecule that drives the swelling attacks.
Key data: In the Phase 3 study announced in August 2025, lonvo-z achieved a 93% reduction in HAE attack rate from baseline across all patients treated. Remarkably, 80% of patients experienced zero attacks in the efficacy assessment period. These results held across all dose levels tested. The therapy was administered as a single one-hour infusion with no serious treatment-related adverse events reported.
Lead company: Intellia Therapeutics
Status: Phase 3 complete. Intellia has announced plans to submit a Biologics License Application (BLA) to the FDA in 2026, with potential approval by late 2026 or early 2027.
Timeline: Approval expected 2026-2027. If approved, lonvo-z would be the first in vivo CRISPR gene editing therapy — a landmark that would demonstrate CRISPR can be delivered directly into the human body, not just to cells in a laboratory dish.
"This is a potential one-and-done treatment that could free patients from a lifetime of injections. The Phase 3 data exceeded our expectations." — John Leonard, M.D., President and CEO, Intellia Therapeutics (Intellia press release, August 2025) [2]
Human cells in culture — in vivo gene editing therapies like lonvo-z deliver CRISPR directly to cells inside the body, eliminating the need for ex vivo cell harvesting. Image: Wikimedia Commons (CC BY-SA 4.0)
4. ATTR Amyloidosis — On Track for Cure by 2028
What it is: Transthyretin (ATTR) amyloidosis is a progressive, life-threatening disease caused by mutations in the TTR gene. The mutant transthyretin protein misfolds and accumulates as amyloid deposits in the heart, nerves, and other organs. Hereditary ATTR amyloidosis affects an estimated 50,000 people worldwide and causes debilitating peripheral neuropathy and cardiomyopathy. Without treatment, patients with cardiac involvement have a median survival of 2.5 to 3.5 years from diagnosis. Current treatments — including the RNA interference drug patisiran and the antisense oligonucleotide inotersen — require ongoing administration and slow disease progression but do not cure it.
The gene editing approach: Intellia Therapeutics' NTLA-2001 (nex-z) is an in vivo CRISPR-Cas9 therapy delivered intravenously via lipid nanoparticles. A single infusion delivers CRISPR components to the liver, where they knock out the TTR gene, dramatically reducing production of the misfolded transthyretin protein. This is conceptually simple: if you stop producing the toxic protein, the body can gradually clear existing amyloid deposits.
Key data: In the Phase 1 study published in The New England Journal of Medicine in June 2021, nex-z achieved serum TTR reductions of up to 93% at the highest dose level after a single infusion. Follow-up data at two years showed that TTR knockdown was durable and sustained without additional dosing. The Phase 3 MAGNITUDE trial is underway, enrolling patients with hereditary ATTR amyloidosis with polyneuropathy.
Lead company: Intellia Therapeutics
Status: Phase 3 (MAGNITUDE trial ongoing). Top-line results expected in 2026-2027. If positive, BLA submission could follow by 2027-2028.
Timeline: Potential approval by 2028. Nex-z is competing against next-generation RNA interference therapies (Alnylam's vutrisiran) that also show strong efficacy, but a one-time CRISPR cure would be a paradigm shift compared to treatments requiring ongoing dosing.
"For the first time, we have shown that CRISPR-Cas9 can be infused intravenously to precisely edit a target gene in the living human body." — Jennifer Doudna, Ph.D., Nobel laureate and co-inventor of CRISPR (commenting on Intellia's early NTLA-2001 data, Nature, 2021) [3]
5. Chronic Granulomatous Disease — Prime Editing Breakthrough
What it is: Chronic granulomatous disease (CGD) is a rare inherited immune deficiency affecting approximately 1 in 200,000 to 250,000 people. It is caused by mutations in genes encoding components of the NADPH oxidase complex — most commonly the CYBB gene on the X chromosome (X-linked CGD). Patients' white blood cells cannot produce the reactive oxygen species needed to kill bacteria and fungi, leaving them vulnerable to severe, recurrent, and life-threatening infections. Patients require lifelong prophylactic antibiotics and antifungals, and many need bone marrow transplants.
The gene editing approach: Prime Medicine is developing PM359, a prime editing therapy for X-linked CGD. Prime editing — invented by David Liu's laboratory at the Broad Institute — is often described as a "search-and-replace" tool for DNA. Unlike standard CRISPR, which cuts both strands of DNA, prime editing makes precise edits without creating double-strand breaks, reducing the risk of unwanted insertions, deletions, or chromosomal rearrangements.
Key data: In preclinical data presented at the American Society of Gene and Cell Therapy (ASGCT) 2025 annual meeting, PM359 achieved a correction rate of 83% in patient-derived stem cells — a remarkable efficiency for prime editing. Corrected cells demonstrated restored NADPH oxidase activity, confirming functional repair of the genetic defect. Prime Medicine plans to file an Investigational New Drug (IND) application to begin human clinical trials.
Lead company: Prime Medicine
Status: Preclinical/IND-enabling. First-in-human trials anticipated by 2026.
Timeline: If clinical trials begin in 2026 and progress on an accelerated timeline (plausible given the severity of the disease and the unmet need), approval could come by 2029-2030. The 83% correction rate in preclinical studies is among the highest ever reported for prime editing, signaling that this next-generation technology is maturing rapidly.
6. Spinal Muscular Atrophy — Already Cured
What it is: Spinal muscular atrophy (SMA) is a devastating neuromuscular disease caused by mutations in the SMN1 gene, which encodes the survival motor neuron protein. Without functional SMN protein, motor neurons in the spinal cord progressively degenerate, leading to muscle weakness, paralysis, and — in the most severe form (Type 1) — death before age two. SMA affects approximately 1 in 10,000 live births and was historically the leading genetic cause of death in infants.
The gene therapy approach: Zolgensma (onasemnogene abeparvovec), developed by Novartis Gene Therapies (now Novartis), is a one-time intravenous gene therapy that uses an AAV9 viral vector to deliver a functional copy of the SMN1 gene. AAV9 was chosen because it can cross the blood-brain barrier and reach motor neurons in the spinal cord. Administered as a single infusion, typically before age two, Zolgensma provides the patient's motor neurons with the instructions they need to produce SMN protein.
Key data: In the pivotal STR1VE trial, all 22 infants treated with Zolgensma before six months of age were alive and event-free (no permanent ventilation needed) at 18 months, compared to a natural history in which approximately 75% of untreated SMA Type 1 infants would require permanent ventilation or die by that age. Long-term follow-up data extending beyond five years show that the therapeutic effect is durable, with treated children reaching motor milestones — sitting, standing, and in some cases walking — that would have been impossible without treatment.
Lead company: Novartis
Status: FDA-approved (May 24, 2019). Now approved in over 40 countries. Also used off-label in older SMA patients in combination with other therapies.
Timeline: Already here. At approximately $2.125 million for a single dose, Zolgensma was the most expensive drug in the world at launch. Novartis has implemented outcomes-based payment models and expanded access programs to broaden availability. The SMA story illustrates the transformative power of gene therapy — and the urgency of newborn screening, since treatment is most effective when given before symptoms appear.
"The most important thing is to treat these babies as early as possible. Every day matters. The earlier you intervene, the more motor neurons you save." — Jerry Mendell, M.D., neurologist and Zolgensma clinical trial lead, Nationwide Children's Hospital [4]
7. Hemophilia B — Already Cured
What it is: Hemophilia B is an X-linked bleeding disorder caused by mutations in the F9 gene, which encodes clotting factor IX. Without sufficient factor IX, patients experience spontaneous and prolonged bleeding episodes, particularly into joints, muscles, and internal organs. Severe hemophilia B affects approximately 1 in 25,000 male births. For decades, treatment has required regular intravenous infusions of factor IX replacement — typically every one to two weeks — at a lifetime cost estimated at $20 million or more.
The gene therapy approach: Hemgenix (etranacogene dezaparvovec), developed by CSL Behring, is a one-time AAV5 gene therapy that delivers a functional copy of the F9 gene to the liver. Liver cells (hepatocytes) are the natural factory for producing clotting factors, so delivering the gene to the right tissue allows the body to begin manufacturing its own factor IX.
Key data: In the pivotal HOPE-B trial, Hemgenix-treated patients achieved a mean factor IX activity level of 39% of normal at 18 months after infusion — well above the 5% threshold needed to convert severe hemophilia to a mild phenotype. The annualized bleeding rate dropped by 64%, and 96% of patients were able to discontinue routine factor IX prophylaxis. Follow-up data at three years confirmed durability of factor IX expression.
Lead company: CSL Behring
Status: FDA-approved (November 22, 2022). At a list price of approximately $3.5 million, Hemgenix was the most expensive single drug in the world at approval — a title it held until surpassed by other gene therapies. A second hemophilia B gene therapy, Beqvez (Pfizer), was approved in April 2024.
Timeline: Already here. Two approved gene therapies for hemophilia B. For hemophilia A, Roctavian (BioMarin) was approved in June 2023, though its factor VIII expression has shown more variability over time. The hemophilia gene therapy landscape is rapidly maturing, with next-generation approaches using engineered AAV capsids and hyperactive factor IX variants in development.
8. Duchenne Muscular Dystrophy — Accelerating Toward a Full Cure
What it is: Duchenne muscular dystrophy (DMD) is one of the most common and devastating genetic diseases in children, affecting approximately 1 in 3,500 to 5,000 male births. It is caused by mutations in the DMD gene — the largest gene in the human genome — which encodes dystrophin, a protein essential for muscle fiber structural integrity. Without dystrophin, muscles progressively weaken and degenerate. Boys with DMD typically lose the ability to walk by age 10-12 and often die from cardiac or respiratory failure in their twenties or thirties.
The gene therapy approach: The approved gene therapy Elevidys (delandistrogene moxeparvovec, Sarepta Therapeutics) uses an AAVrh74 vector to deliver a shortened version of the dystrophin gene (micro-dystrophin) to muscle cells. Because the full DMD gene is too large to fit inside an AAV vector (the gene spans 2.4 million base pairs, while AAV can carry roughly 4,700), researchers engineered a miniaturized version that retains the critical functional domains.
Meanwhile, several groups are pursuing CRISPR-based approaches that could offer a more complete solution. Exon-skipping strategies using CRISPR could permanently correct the reading frame of the DMD gene, enabling production of a partially functional dystrophin protein. Researchers at UT Southwestern, led by Eric Olson, have demonstrated in vivo CRISPR correction of DMD mutations in animal models, and multiple CRISPR programs are advancing toward clinical trials.
Key data: Elevidys received accelerated FDA approval in June 2023 for ambulatory DMD patients aged 4-5 years. In the confirmatory EMBARK trial, Elevidys demonstrated significant micro-dystrophin expression in muscle tissue (averaging 36% of normal dystrophin levels) but missed the primary endpoint of improved motor function on the North Star Ambulatory Assessment at 52 weeks. However, a pre-specified secondary analysis showed statistically significant improvement in patients under age 8, and the therapy demonstrated clinically meaningful stabilization of muscle function compared to natural disease progression.
Lead companies: Sarepta Therapeutics (Elevidys); multiple CRISPR programs in preclinical/early clinical development
Status: Elevidys is FDA-approved under accelerated approval. CRISPR-based DMD programs remain preclinical or early Phase 1. The combination of gene replacement (Elevidys) with future CRISPR approaches could eventually offer a more complete treatment.
Timeline: Gene therapy for DMD is already here, but a "full cure" — restoring full-length dystrophin and halting all disease progression — remains an aspiration for 2028-2030. The size of the dystrophin gene makes it one of the hardest targets in all of gene therapy, but CRISPR exon-skipping strategies and next-generation delivery vectors are closing the gap.
"DMD is arguably the most challenging target in gene therapy because of the sheer size of the dystrophin gene. But the progress we have made in the last five years would have been unimaginable a decade ago." — Eric Olson, Ph.D., Professor of Molecular Biology, UT Southwestern Medical Center [5]
9. Familial Hypercholesterolemia — Base Editing Takes on Heart Disease
What it is: Familial hypercholesterolemia (FH) is one of the most common inherited genetic disorders, affecting approximately 1 in 250 people — roughly 31 million people worldwide. It is caused by mutations in genes involved in LDL cholesterol clearance, most commonly the LDLR gene (LDL receptor), APOB, or PCSK9. People with FH have dangerously elevated LDL cholesterol levels from birth, leading to premature atherosclerosis and heart disease. Heterozygous FH doubles or triples the risk of coronary artery disease by age 50. Homozygous FH, though rarer (about 1 in 300,000), is even more severe, with heart attacks sometimes occurring in childhood.
The gene editing approach: Verve Therapeutics (now partnered with Eli Lilly following Lilly's acquisition) is developing a base editing therapy that uses a single intravenous infusion to permanently inactivate the PCSK9 gene in liver cells. PCSK9 is a protein that promotes degradation of LDL receptors on the liver surface. By knocking out PCSK9 via adenine base editing (which converts a single A-T base pair to a G-C pair without cutting the DNA), the therapy permanently increases the number of LDL receptors available to clear cholesterol from the blood.
This is the same biological mechanism exploited by blockbuster PCSK9 inhibitor drugs like evolocumab (Repatha) and alirocumab (Praluent), which require injections every two to four weeks. The base editing approach aims to achieve the same effect with a single treatment — forever.
Key data: In the Phase 1b heart-1 trial, Verve's VERVE-101 demonstrated dose-dependent reductions in blood PCSK9 protein (up to 84% reduction) and LDL cholesterol (up to 55% reduction) after a single infusion in patients with heterozygous FH. However, a serious adverse event — a fatal cardiac event in one patient with pre-existing severe coronary artery disease — led to a clinical hold and a refocusing of the program toward patients with homozygous FH, who have the most severe disease and the greatest unmet need.
Eli Lilly's acquisition of Verve in early 2025 brought massive resources and cardiovascular expertise to the program. The next-generation candidate, VERVE-102, uses an improved lipid nanoparticle formulation and is advancing into clinical trials.
Lead company: Verve Therapeutics / Eli Lilly
Status: Phase 1b (VERVE-101); next-generation VERVE-102 entering clinical development. Lilly has signaled a commitment to advancing the program through registration trials.
Timeline: A potential approval by 2029-2030 for homozygous FH. If successful, this would represent a seismic shift in cardiovascular medicine — the first one-time genetic treatment for the world's leading cause of death. The broader implications for common diseases are enormous: if you can use gene editing to permanently lower cholesterol, the same approach could theoretically target other cardiovascular risk factors.
10. Leber Congenital Amaurosis — CRISPR Restores Sight
What it is: Leber congenital amaurosis (LCA) is a group of inherited retinal dystrophies that cause severe vision loss or blindness from birth or early infancy. LCA type 10 (LCA10), the most common form, is caused by mutations in the CEP290 gene. These mutations create an abnormal splice site that produces a truncated, nonfunctional CEP290 protein, leading to degeneration of photoreceptor cells in the retina. Approximately 1 in 40,000 children are born with LCA.
A first-generation gene therapy for a different form of LCA already exists: Luxturna (Spark Therapeutics/Roche), approved in 2017, treats LCA caused by RPE65 mutations. But LCA10 caused by CEP290 mutations could not be addressed by the same approach — the CEP290 gene is too large to fit inside an AAV vector.
The gene editing approach: Editas Medicine developed EDIT-101, the first CRISPR gene editing therapy administered directly into the human body (in vivo). EDIT-101 uses an AAV5 vector to deliver CRISPR-Cas9 components via subretinal injection — directly under the retina, millimeters from the photoreceptor cells that need correction. The CRISPR system is designed to remove or invert the pathogenic intronic mutation in CEP290, restoring normal splicing and functional protein production.
Key data: In the Phase 1/2 BRILLIANCE trial, EDIT-101 demonstrated clinically meaningful improvements in vision in several patients, including improvements in light sensitivity, visual acuity, and the ability to navigate a mobility course under dim lighting. One patient, Carlene Knight, reported being able to see colors and shapes for the first time in her life. While the results were encouraging, they were also variable across patients, reflecting the challenges of treating a degenerative disease at different stages of photoreceptor loss.
Editas has since paused its own development of EDIT-101, but the BRILLIANCE trial data represent an important proof of concept that CRISPR can work when injected directly into the body. Multiple other groups, including those using base editing and next-generation CRISPR approaches, are now pursuing inherited retinal diseases.
Lead company: Editas Medicine (EDIT-101, paused); multiple next-generation programs in development
Status: Phase 1/2 (BRILLIANCE trial completed). The technology has been validated in humans, and next-generation programs with improved editing efficiency and delivery are advancing.
Timeline: A refined CRISPR or base editing therapy for LCA10 could reach approval by 2029-2030, building on the foundational data from BRILLIANCE and improved delivery technologies. The broader category of inherited retinal diseases is one of the most active areas in gene therapy, with the eye being an ideal target organ — small, accessible, immune-privileged, and easy to monitor for treatment effects.
"Carlene's case was a breakthrough. When she told us she could see colors for the first time, it was one of the most moving moments of my career." — Eric Pierce, M.D., Ph.D., Director of the Inherited Retinal Disorders Service at Massachusetts Eye and Ear and BRILLIANCE trial investigator [6]
What "Cured" Actually Means
Before looking ahead, it is worth pausing on what we mean by "cure" in the context of gene therapy. For most of these diseases, a cure means a one-time treatment that eliminates the root genetic cause, restores normal or near-normal function, and does not require ongoing therapy. By that definition, several diseases on this list — sickle cell disease, beta-thalassemia, SMA (when treated early), and hemophilia B — already have functional cures available today.
But "cured" at the individual level is different from "cured" at the population level. Even for approved therapies, significant barriers remain:
- Cost: Gene therapies range from $2 million to $4.25 million per treatment. While cost-effectiveness analyses often favor one-time cures over lifetime management costs, the upfront price creates massive challenges for health systems and insurers.
- Access: Treatments require specialized centers with expertise in stem cell transplantation, gene therapy manufacturing, or retinal surgery. Many patients live far from these centers.
- Manufacturing: Gene therapies are complex biological products. Manufacturing a personalized ex vivo therapy takes weeks to months per patient, creating bottlenecks that limit how many patients can be treated per year.
- Global equity: The diseases on this list disproportionately affect people in low- and middle-income countries — particularly sickle cell disease in sub-Saharan Africa — where the current treatment infrastructure and pricing models are not viable.
These are solvable problems, but they require sustained effort from policymakers, payers, manufacturers, and patient advocates. A cure that exists but cannot reach the patients who need it is, in practical terms, not yet a cure.
The Bigger Picture: Why the Next Five Years Matter
The 10 diseases listed here represent a snapshot of a field in rapid acceleration. Several broader trends are converging to make the period from 2025 to 2030 potentially the most transformative in the history of genetic medicine:
-
In vivo delivery is maturing: The early gene therapies (Casgevy, Zolgensma) required either ex vivo cell processing or viral vectors with limited tissue targeting. The newest programs from Intellia, Verve, and others deliver gene editing components directly into the body using lipid nanoparticles, dramatically simplifying the treatment process and opening the door to diseases in organs that were previously unreachable.
-
Next-generation editing tools are entering the clinic: Base editing, prime editing, and epigenetic editing offer greater precision and fewer safety concerns than standard CRISPR-Cas9 cutting. As these tools mature, the range of correctable mutations expands enormously. David Liu, the inventor of base editing and prime editing, has estimated that these tools could theoretically address approximately 89% of known pathogenic point mutations.
-
Regulatory pathways are established: The FDA, EMA, and other regulatory agencies have now approved multiple gene therapies across different technology platforms. The regulatory pathway — while still rigorous — is no longer uncharted territory. Accelerated approval pathways for serious diseases with unmet need continue to shorten timelines.
-
Manufacturing is scaling: Companies are investing billions in gene therapy manufacturing infrastructure. Viral vector production, lipid nanoparticle formulation, and cell processing capabilities are expanding globally. The cost per treatment is expected to decrease as manufacturing scales and competition increases.
-
Newborn screening is expanding: For diseases like SMA, early treatment is dramatically more effective than late treatment. Newborn screening programs that test for genetic diseases at birth are expanding worldwide, ensuring that babies are identified and treated before irreversible damage occurs.
The promise of genetic medicine has always been that if you understand the cause of a disease at the DNA level, you can fix it. For the first time in history, that promise is being delivered — one disease at a time.
Sources & Further Reading
- NPR: Victoria Gray's CRISPR sickle cell story — Coverage of FDA approval and Victoria Gray's journey.
- Intellia Therapeutics: NTLA-2002 Phase 3 results — Press release on lonvo-z Phase 3 data for hereditary angioedema.
- Gillmore, J.D. et al. "CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis." The New England Journal of Medicine (2021). DOI: 10.1056/NEJMoa2107454
- Mendell, J.R. et al. "Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy." The New England Journal of Medicine (2017). DOI: 10.1056/NEJMoa1706198
- Sarepta Therapeutics: Elevidys EMBARK trial results — Trial data on micro-dystrophin gene therapy for DMD.
- Maeder, M.L. et al. "Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10." Nature Medicine (2019). DOI: 10.1038/s41591-018-0327-9
- FDA: Approved Cellular and Gene Therapy Products — Official FDA list of approved products.
- Frangoul, H. et al. "CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Beta-Thalassemia." The New England Journal of Medicine (2021). DOI: 10.1056/NEJMoa2031054
- CSL Behring: Hemgenix prescribing information — Hemophilia B gene therapy clinical data and outcomes.
- Prime Medicine: ASGCT 2025 data presentations — Preclinical data on PM359 for chronic granulomatous disease.
- Verve Therapeutics / Eli Lilly: heart-1 trial results — Phase 1b base editing data for familial hypercholesterolemia.
- Editas Medicine: BRILLIANCE trial update — Phase 1/2 data on EDIT-101 for Leber congenital amaurosis type 10.
- Anzalone, A.V. et al. "Search-and-replace genome editing without double-strand breaks or donor DNA." Nature (2019). DOI: 10.1038/s41586-019-1711-4 — Original prime editing publication from David Liu's lab.
Last updated: November 2025.
